Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- BNTC
- Price
- 12.83
- Stock movement up
- +0.71 (5.86%)
- Company name
- Benitec Biopharma Ltd ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 434.45M
- Ent value
- 342.40M
- Price/Sales
- 781.39
- Price/Book
- 4.64
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -62.31%
- 1 year return (CAGR)
- 19.13%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BNTC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 781.39 |
| Price to Book | 4.64 |
| EV to Sales | 615.83 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 33.86M |
| EPS (TTM) | -1.12 |
| FCF per share (TTM) | -0.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 556.00K |
| Gross profit (TTM) | -87.52K |
| Operating income (TTM) | -50.80M |
| Net income (TTM) | -46.42M |
| EPS (TTM) | -1.12 |
| EPS (1y forward) | -0.92 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -15.74% |
| Operating margin (TTM) | -9137.58% |
| Profit margin (TTM) | -8349.13% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 94.48M |
| Net receivables | 7.00K |
| Total current assets | 95.08M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.36M |
| Total assets | 96.03M |
| Accounts payable | 271.00K |
| Short/Current long term debt | 817.00K |
| Total current liabilities | 2.02M |
| Total liabilities | 2.43M |
| Shareholder's equity | 93.60M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -22.67M |
| Capital expenditures (TTM) | 18.47K |
| Free cash flow (TTM) | -22.38M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -49.60% |
| Return on Assets | -48.34% |
| Return on Invested Capital | -49.38% |
| Cash Return on Invested Capital | -23.81% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.16 |
| Daily high | 12.90 |
| Daily low | 12.15 |
| Daily Volume | 111K |
| All-time high | 5598.27 |
| 1y analyst estimate | 25.00 |
| Beta | 0.20 |
| EPS (TTM) | -1.12 |
| Dividend per share | 0.00 |
| Ex-div date | 1 Jun 2018 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BNTC | S&P500 | |
| Current price drop from All-time high | -99.77% | -0.89% |
| Highest price drop | -99.83% | -19.00% |
| Date of highest drop | 9 Oct 2024 | 8 Apr 2025 |
| Avg drop from high | -99.77% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
434.45M
Marketcap category
Small-cap
Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Employees
19
Website
Investor relations
-
SEC filings
CEO
Jerel A. Banks
Country
USA
City
Melbourne
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page